Equities

ProQR Therapeutics NV

ProQR Therapeutics NV

Actions
  • Price (MXN)36.00
  • Today's Change0.00 / 0.00%
  • Shares traded730.00
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Sep 12 2024 12:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments11995188
Total Receivables, Net0.75570.27
Total Inventory------
Prepaid expenses0.792.453.14
Other current assets, total0.520.610.56
Total current assets121154191
Property, plant & equipment, net171617
Goodwill, net------
Intangibles, net------
Long term investments00.620.63
Note receivable - long term------
Other long term assets------
Total assets138171210
LIABILITIES
Accounts payable1.540.390.19
Accrued expenses1.661.121.23
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.613.896.31
Other current liabilities, total291620
Total current liabilities342128
Total long term debt181854
Total debt202260
Deferred income tax------
Minority interest0(0.38)(0.6)
Other liabilities, total446715
Total liabilities9610696
SHAREHOLDERS EQUITY
Common stock------
Additional paid-in capital416416401
Retained earnings (accumulated deficit)(401)(381)(318)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity4165114
Total liabilities & shareholders' equity138171210
Total common shares outstanding848475
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.